| 20.01 -0.56 (-2.72%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.75 | 1-year : | 28.91 |
| Resists | First : | 21.19 | Second : | 24.75 |
| Pivot price | 19.28  |
|||
| Supports | First : | 18.56 | Second : | 16.94 |
| MAs | MA(5) : | 20.33 |
MA(20) : | 19.38 |
| MA(100) : | 16.35 |
MA(250) : | 17.36  |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 81.3 |
D(3) : | 85.1 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 25.54 | Low : | 10.96 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CDNA ] has closed below upper band by 32.2%. Bollinger Bands are 66.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 20.87 - 20.98 | 20.98 - 21.08 |
| Low: | 19.69 - 19.82 | 19.82 - 19.92 |
| Close: | 19.81 - 20.02 | 20.02 - 20.19 |
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Tue, 13 Jan 2026
Implied Volatility Surging for CareDx Stock Options - Yahoo Finance
Tue, 13 Jan 2026
CareDx (CDNA) Is Up 9.4% After Strong 2025 Outlook And 10x Genomics Tie-Up - Has The Bull Case Changed? - Yahoo Finance
Mon, 12 Jan 2026
CareDx Preliminary Q4 Revenue Up 25% - Nasdaq
Mon, 12 Jan 2026
Transplant test maker CareDx reports 25% jump in late‑2025 revenue - Stock Titan
Fri, 26 Dec 2025
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mon, 22 Dec 2025
CareDX Has Reached An Inflection Point, But Regulatory Risks Remain (Upgrade) (CDNA) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 51 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 101.8 (%) |
| Shares Short | 6,260 (K) |
| Shares Short P.Month | 6,960 (K) |
| EPS | 1.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.05 |
| Profit Margin | 19.6 % |
| Operating Margin | -0.3 % |
| Return on Assets (ttm) | -4.1 % |
| Return on Equity (ttm) | 24.1 % |
| Qtrly Rev. Growth | 20.7 % |
| Gross Profit (p.s.) | 4.7 |
| Sales Per Share | 6.96 |
| EBITDA (p.s.) | -0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 43 (M) |
| Levered Free Cash Flow | 43 (M) |
| PE Ratio | 15.63 |
| PEG Ratio | 0 |
| Price to Book value | 3.3 |
| Price to Sales | 2.87 |
| Price to Cash Flow | 24.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|